- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03483558
Vegetable Signature From Human Metabolomics Responses
March 28, 2018 updated by: National Health Research Institutes, Taiwan
Dietary Intervention Studies on a Variety of Vegetables
The purpose of this study is to perform dietary intervention studies on a variety of vegetables.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Plant-based foods have always been an important component of a healthy diet.
High intake of plant foods may not only maintain normal bodily functions through the provision of dietary fiber, vitamins, and minerals but also relieve symptoms and prevent diseases.
Many studies have pointed out that high intake of plant foods may reduce the incidence of non-communicable disease.
Past research investigating the effect of phytochemicals has usually been limited to single substances or single foods.
However, a number of researchers have pointed out that phytonutrients and dietary components are likely to act synergistically.Health effects and mechanisms of phytonutrients in combination have not been carefully studied in population settings.
The technology of metabolomics has enabled the simultaneous measurement of hundreds of small molecules in biological samples.
Exploring the change of metabolites after feeding can not only help us understand the role of plant foods, but may also provide opportunities to assess plant food intake levels.
Study Type
Interventional
Enrollment (Actual)
13
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI 18.5~30 kg/m2
- non-smoker
- non-alcoholic
Exclusion Criteria:
- Unwilling to stop taking the dietary supplements that may affect the experiment result.
- Unwilling to take the provided meal during the designated period.
- Taking hypertension or diabetes drugs.
- Diagnosed immune diseases (such as allergic diseases, autoimmune diseases, etc.), liver diseases, metabolic diseases (such as hyperthyroidism or hypothyroidism), or other not suitable for the dietary study.
- Diagnosed cancer or other severe diseases.
- Suffered from urinary tract infection or took antibiotic in the past three months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Control
Participants were fed a standardized diet (without any vegetables) in this experiment.
|
A standardized diet without any vegetables was provided.
|
EXPERIMENTAL: Spinach
Participants were fed a standardized diet with 200g spinach in this experiment.
|
A standardized diet with 200g spinach was provided.
|
EXPERIMENTAL: Celery
Participants were fed a standardized diet with 200g celery in this experiment.
|
A standardized diet with 200g celery was provided.
|
EXPERIMENTAL: Onion
Participants were fed a standardized diet with 200g onion in this experiment.
|
A standardized diet with 200g onion was provided.
|
EXPERIMENTAL: Mixed Vegetables
Participants were fed a standardized diet with 200g of mixed vegetables (spinach, celery, and onion) in this experiment.
|
A standardized diet with 200g of mixed vegetables (spinach, celery, and onion) was provided.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intensities of multiple serum metabolites
Time Frame: Baseline (fasting state before breakfast at 7:30AM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
Baseline (fasting state before breakfast at 7:30AM)
|
Intensities of multiple serum metabolites
Time Frame: 4 Hours (immediately before lunch at 11:30AM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
4 Hours (immediately before lunch at 11:30AM)
|
Intensities of multiple serum metabolites
Time Frame: 5.5 hours (after lunch at 13:00PM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
5.5 hours (after lunch at 13:00PM)
|
Intensities of multiple serum metabolites
Time Frame: 6.5 hours (after lunch at 14:00 PM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
6.5 hours (after lunch at 14:00 PM)
|
Intensities of multiple serum metabolites
Time Frame: 7.5 hours (after lunch at 15:00PM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
7.5 hours (after lunch at 15:00PM)
|
Intensities of multiple serum metabolites
Time Frame: 8.5 hours (after lunch at 16:00PM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
8.5 hours (after lunch at 16:00PM)
|
Intensities of multiple serum metabolites
Time Frame: 9.5 hours (after lunch at 17:00PM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
9.5 hours (after lunch at 17:00PM)
|
Intensities of multiple serum metabolites
Time Frame: 10.5 hours (after lunch at 18:00PM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
10.5 hours (after lunch at 18:00PM)
|
Intensities of multiple serum metabolites
Time Frame: 11.5 hours (after lunch at 19:00PM)
|
The outcome measure consists of intensities of multiple serum metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
11.5 hours (after lunch at 19:00PM)
|
Intensities of multiple urinary metabolites
Time Frame: Baseline (overnight urine sample collected at 7:30AM)
|
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
Baseline (overnight urine sample collected at 7:30AM)
|
Intensities of multiple urinary metabolites
Time Frame: 3.5~4 hours (before lunch urine sample collected during 11:00~11:30AM)
|
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
3.5~4 hours (before lunch urine sample collected during 11:00~11:30AM)
|
Intensities of multiple urinary metabolites
Time Frame: 4.5~6.5 hours (2-hour after lunch urine sample collected from 12:00 to 14:00PM)
|
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
4.5~6.5 hours (2-hour after lunch urine sample collected from 12:00 to 14:00PM)
|
Intensities of multiple urinary metabolites
Time Frame: 6.5~8.5 hours (4-hour after lunch urine sample collected from 14:00 to 16:00PM)
|
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
6.5~8.5 hours (4-hour after lunch urine sample collected from 14:00 to 16:00PM)
|
Intensities of multiple urinary metabolites
Time Frame: 8.5~11.5 hours (7-hour after lunch urine sample collected from 16:00 to 19:00PM)
|
The outcome measure consists of intensities of multiple urinary metabolites from a liquid chromatography/time-of-flight/mass spectrometry (LC/TOF/MS) experiment.
Intensity means the level of response variable (a given metabolite) showing the degree of response detected by LC/TOF/MS.
|
8.5~11.5 hours (7-hour after lunch urine sample collected from 16:00 to 19:00PM)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 11, 2011
Primary Completion (ACTUAL)
December 31, 2012
Study Completion (ACTUAL)
May 28, 2015
Study Registration Dates
First Submitted
January 31, 2018
First Submitted That Met QC Criteria
March 28, 2018
First Posted (ACTUAL)
March 30, 2018
Study Record Updates
Last Update Posted (ACTUAL)
March 30, 2018
Last Update Submitted That Met QC Criteria
March 28, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- NHRI_EC0991003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Control
-
Claudia M. WittCompleted
-
University of California, San FranciscoWithdrawn
-
Universidad Nacional de Educación a DistanciaMinisterio de Economía y Competitividad, SpainUnknownChronic Pain | FibromyalgiaSpain
-
University of California, Los AngelesThe National Council on Aging; City of Los Angeles Department of Aging; Los Angeles...Completed
-
Queen's University, BelfastPublic Health Agency, Health and Social Care Research and Development; Tiny...Completed
-
National Taiwan University HospitalEnrolling by invitationCognitive Function | Atrial Fibrillation, PersistentTaiwan
-
Takeshi MorimotoUniversity of the RyukyusActive, not recruitingCoronary Artery Disease | Hypertension | Type 2 Diabetes | DyslipidemiaJapan
-
Johnson & Johnson Vision Care, Inc.TerminatedRefractive Error CorrectionUnited States
-
Vanderbilt University Medical CenterCompleted
-
Yonsei UniversityNot yet recruitingHypertension | Chronic Kidney Diseases | DyslipidemiasKorea, Republic of